Panacea Biotec Board of Directors

Get the latest insights into the leadership at Panacea Biotec. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr. Rajesh Jain Chairman & Managing Director
Mr. Sandeep Jain Joint Managing Director
Mr. Ankesh Jain Whole Time Director
Mrs. Ambika Sharma Non Executive Director
Mr. N N Khamitkar Non Executive Director
Mr. Mukul Gupta Non Executive Director
Mr. Narotam Kumar Juneja Non Executive Director
Mr. K M Lal Non Executive Director
Mrs. Manjula Upadhyay Non Executive Director
Mr. Bhupinder Singh Non Executive Director

Panacea Biotec Share price

PANACEABIO

407.45

16.35 (-3.86%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:44 IST
BUYSELL
Today's High

429.55

Today's Low

406.00

52 Week Low

220.00

52 Week High

581.90

The current prices are delayed, login to your account for live prices

Panacea Biotec FAQs

The board at Panacea Biotec consists of experienced professionals, including Dr. Rajesh Jain , Mr. Sandeep Jain , and others, overseeing the company’s strategic and corporate governance.

Directors at Panacea Biotec are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr. Rajesh Jain is the current chairman at Panacea Biotec.

Executive directors at Panacea Biotec are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Panacea Biotec adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Panacea Biotec, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.